Application of licoflavone C and active phenolic acid or pharmaceutically acceptable salt thereof in preparation of medicine or inhibitor for resisting segmented RNA virus

By using endonucleases for segmented RNA viruses such as licorice flavonoid C and active phenolic acids, the lack of targeted EN inhibitors for multiple segmented RNA viruses in the prior art has been solved, and the problem of achieving the goal of segmented RNA viruses is achieved. The broad-spectrum antiviral effect is provided, and antiviral drugs with multiple pharmacological activities and clear targets are provided.

CN119055630AActive Publication Date: 2024-12-03WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI

Patent Information

Application Number
CN202411226297.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-03
Estimated Expiration
2044-09-03

AI Technical Summary

Technical Problem

The existing anti-segment negative-strand RNA virus drugs are mainly concentrated in influenza virus inhibitors, and there are fewer targeted EN inhibitors for other segmented RNA viruses. The mechanism of antiviral effects of traditional Chinese medicine is shallow, and there is a lack of broad spectrum. Antiviral drugs.

Method used

Licorice flavonoid C and its pharmaceutical salts, active phenolic acids (such as sanphenolic acid A, B, C) and other flavonoids as Cap-dependent endonuclease inhibitors to target segmented RNA virus endocardial Enzymes that inhibit viral replication and transmission.

Benefits of technology

These compounds show broad-spectrum antiviral activity, which can effectively inhibit the endonuclease activity and viral replication of multiple segmented RNA viruses, provide multiple pharmacological activities and clear target antiviral candidates, enriching the broad-spectrum antiviral Type of medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055630A_ABST
    Figure CN119055630A_ABST
Patent Text Reader

Abstract

The invention discloses application of licoflavone C and active phenolic acid or pharmaceutically acceptable salt thereof in preparation of drugs or inhibitors for resisting segmented RNA viruses, and relates to the technical field of virus resistance. The licoflavone C and the active phenolic acid target the Cap-dependent endonuclease of the segmented RNA virus so as to play a broad-spectrum antiviral role, and the licoflavone C and the active phenolic acid target is a broad-spectrum antiviral candidate drug with a clear target spot, and the proposal of the invention provides a good reference drug for research and development of antiviral drugs. Besides, the licoflavone C analogues are further subjected to anti-segmented RNA virus experiments, results show that multiple licoflavone C analogues have the effects of resisting segmented RNA virus activity at a cellular level and inhibiting segmented RNA virus endonuclease activity in vitro, and the broad-spectrum antiviral drug types are enriched.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antiviral technology, and in particular to the use of glycyrrhizin flavone C and active phenolic acid or pharmaceutically acceptable salts thereof in the preparation of drugs or inhibitors against segmented RNA viruses. Background Art

[0002] Segmented negative-strand RNA viruses are mainly distributed in the families of Orthomyxoviridae, Leucoviridae, Naroviridae and Arenaviridae, and representative viruses include influenza A virus (IAV), severe fever with thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV). Segmented negative-strand RNA viruses rely on a unique "cap-snatching" mechanism during transcription. Taking Bunyavirus as an example, the cap-snatching process is performed by the L protein encoded by the virus. The N-terminus of the L protein is the endonuclease (EN) domain, the middle is the RNA-dependent RNA polymerase (RdRP), and the C-terminal cap binding domain (CBD). Under the synergistic effect of CBD, EN realizes the cap cutting of host mRNA. The oligonucleotide containing the 5' cap structure obtained by cutting is used as a primer for RdRP transcription, so EN can be used as an important target for viral intervention. However, there is only one EN inhibitor for influenza virus on the market, namely baloxavir, and more antiviral drugs targeting EN are urgently needed to be discovered.

[0003] As a traditional Chinese medicine, Chinese medicine has a very rich variety of pharmacologically active ingredients and has a significant preventive and therapeutic effect on viral infections. In the treatment of novel coronavirus infection, antiviral Chinese medicine preparations have played a vital role. These Chinese medicine preparations have become a valuable source for new drug development because of their novelty, multi-component, and multi-target characteristics. In recent years, some progress has been made in the study of the antiviral mechanism of Chinese medicine, but there are still many issues that need to be further explored. Therefore, the screening of effective antiviral ingredients of Chinese medicine and the evaluation of their pharmacological efficacy are important directions for future research.

[0004] Flavonoids, also known as flavonoids, are widely present in various tissues of plants. They are an important class of plant secondary metabolites that can help plants resist invasion by bacteria, fungi, etc. The basic skeleton of flavonoids is C6-C3-C6, and its parent nucleus is mainly composed of two benzene rings connected by a heterocyclic pyran ring. Different flavonoids have shown significant antiviral properties in in vitro and in vivo studies. For example, baicalein and baicalin can inhibit the activity of 3CLpro, an important protease in the new coronavirus, thereby inhibiting the replication of the virus.

[0005] Phenolic acid compounds refer to aromatic carboxylic acid compounds with multiple phenolic hydroxyl groups substituted on a benzene ring. They are widely found in many plants, especially some common Chinese medicines, such as Salvia miltiorrhiza, honeysuckle, and forsythia. At present, phenolic acid compounds have significant effects in anti-inflammatory, antioxidant, anti-tumor, anti-bacterial and anti-fungal effects, but there are few reports on their clinical use in antiviral aspects, and the research on their mechanism of action is relatively shallow. Therefore, the development of such substances has broad prospects.

[0006] In view of the above, based on the structural diversity and pharmacological activity of Chinese medicine monomer compounds, it is of great value to discover and develop drugs against segmented negative-strand RNA viruses. In view of this, the present invention is proposed. Summary of the invention

[0007] The object of the present invention is to provide the use of glycyrrhizin flavone C and active phenolic acid or pharmaceutically acceptable salts thereof in the preparation of drugs or inhibitors against segmented RNA viruses.

[0008] The present invention is achieved in that:

[0009] In a first aspect, the present invention provides the use of glycyrrhizin C or a pharmaceutically acceptable salt thereof in the preparation of a drug against segmented RNA viruses or a Cap-dependent endonuclease inhibitor.

[0010] In a second aspect, the present invention provides the use of an active phenolic acid or a pharmaceutically acceptable salt thereof in the preparation of a drug against a segmented RNA virus or a Cap-dependent nuclease inhibitor, wherein the active phenolic acid is selected from at least one of salvianolic acid A, salvianolic acid B and salvianolic acid C, and the segmented RNA virus is selected from the viruses in the Bunyavirales order.

[0011] In a third aspect, the present invention provides the use of flavonoids or pharmaceutically acceptable salts thereof in the preparation of drugs against segmented RNA viruses or Cap-dependent nuclease inhibitors, wherein the flavonoids are selected from at least one of glycyrrhiza flavonoid A, glycyrrhiza isoflavone A, glycyrrhiza flavonoid B, glycyrrhiza flavonols, glabridol, northwest glycyrrhiza isoflavones, luteolin, mulberry flavonoids, sophora flavescens alcohol A, dehydrated icariin, isodehydroicariin, isopsoralen dihydroflavone, isoxanthohumol and paper mulberry flavonol F.

[0012] The present invention has the following beneficial effects:

[0013] The present invention screens out natural monomer compounds with broad-spectrum resistance to segmented RNA viruses, wherein licorice flavonoids C is derived from the Chinese medicinal material licorice, and salvianolic acids A, B, and C are derived from the Chinese medicinal material salvia miltiorrhiza, which have multiple pharmacological activities. Experiments have shown that these two types of compounds target the Cap-dependent nuclease of segmented RNA viruses and exert broad-spectrum antiviral effects, and are candidate broad-spectrum antiviral drugs with clear targets. The invention provides a good reference drug for the research and development of antiviral drugs.

[0014] In addition, the present invention also conducted anti-segmented RNA virus experiments on glycyrrhizin C analogs (flavonoids), and the results showed that a variety of glycyrrhizin C analogs (flavonoids) had anti-segmented RNA virus activity at the cellular level and the effect of inhibiting segmented RNA virus endonuclease activity in vitro. The invention enriches the types of broad-spectrum antiviral drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0016] Figure 1 This is a graph showing the results of the test of the inhibitory effects of licorice flavonoids C and salvianolic acids A, B, and C on the enzyme activity of segmented negative-strand RNA viruses SFTSV, HRTV, GTV, LCMV, and IAV endonuclease EN;

[0017] Figure 2 The results of the antiviral activity test of licorice flavonoids C and salvianolic acids A, B, and C against SFTSV, HRTV, GTV, LCMV, and IAV are shown;

[0018] Figure 3 This is the result of the antiviral activity test of licorice flavonoids C and salvianolic acid A, B, C in a mouse model;

[0019] Figure 4 The graph shows the anti-SFTSV experimental results of 16 natural flavonoid extracts at the in vitro and cell levels. DETAILED DESCRIPTION

[0020] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0021] In a first aspect, the present invention provides the use of glycyrrhizin C or a pharmaceutically acceptable salt thereof in the preparation of a drug against segmented RNA viruses or a Cap-dependent endonuclease inhibitor.

[0022] Anti-segmented RNA virus includes but is not limited to: inhibiting the load of segmented RNA viruses in the host, reducing the number of viral copies, inhibiting the expression level of viral genomic RNA, and inhibiting the nuclease activity in the virus.

[0023] The copy number of a virus refers to the copy number of the RNA segment encoding hemagglutinin (HA), the copy number of the RNA segment encoding neuraminidase (NA), and the like.

[0024] The inventors have confirmed through in vivo and in vitro experiments that licorice flavonoids C has obvious anti-segmented RNA virus activity and can inhibit the activity of the Cap-dependent nuclease of the segmented RNA virus. Since the RNA polymerase that the viral RNA depends on is composed of three subunits, namely PB1, PB2 and PA, and is highly conserved in the three influenza viruses A, B, and C, it is responsible for completing the replication and transcription of the viral genome. Among them, PB2 grabs the host cell mRNA through the "Cap-snatching" mechanism, and the N-terminal domain of the PA subunit shears the mRNA, exerts endonuclease activity, and produces oligoribonucleotides with cap structures for the generation and transcription of viral mRNA. Therefore, PA plays an important role in the replication process of influenza virus, and inhibiting the activity of PA can effectively inhibit the replication of influenza virus, thereby controlling the spread of influenza virus. The present invention inhibits the replication of influenza virus by inhibiting the activity of the Cap-dependent nuclease of segmented RNA virus, thereby achieving the inhibition of viral activity. Therefore, Cap-dependent nuclease inhibitors have good potential for treating segmented RNA viruses including influenza.

[0025] Licorice flavonoids C or its pharmaceutically acceptable salt has good application prospects in preventing and / or treating diseases caused by viruses with Cap-dependent nucleases. In an optional embodiment, the disease is a related disease or condition caused by influenza virus.

[0026] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus in the Bunyavirales and Orthomyxoviridae.

[0027] Segmented RNA viruses are segmented negative-strand RNA viruses.

[0028] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales.

[0029] The segmented RNA virus is selected from at least one of Severefever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the family Leucoviridae. The viruses of the family Leucoviridae include but are not limited to the genus Geckovirus, the genus Parsivirus, the genus Termitovirus and the genus Tenuivirus.

[0030] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one of Songling virus (SGLV) and Crimean Congo hemorrhagic fever virus (CCHFV) under the Nairoviridae family;

[0031] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one of the lymphocytic choriomeningitis virus LCMV, Machupo virus (MACV) and Lassa virus under the Arenaviridae family;

[0032] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the genus Influenza A virus, genus Influenza B virus, genus Influenza C virus and genus Togotovirus under the family Orthomyxoviridae.

[0033] In a preferred embodiment of the present invention, the application includes: Licorice flavonoids C inhibits viral activity by targeting the Cap-dependent nuclease of segmented RNA viruses.

[0034] In a second aspect, the present invention provides the use of an active phenolic acid or a pharmaceutically acceptable salt thereof in the preparation of a drug against a segmented RNA virus or a Cap-dependent nuclease inhibitor, wherein the active phenolic acid is selected from at least one of salvianolic acid A, salvianolic acid B and salvianolic acid C, and the segmented RNA virus is selected from the viruses in the Bunyavirales order.

[0035] In vivo and in vitro experiments confirmed that active phenolic acids have good inhibitory activity against segmented RNA viruses.

[0036] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales.

[0037] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the Leukoviridae family.

[0038] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus selected from Songling virus (SGLV) and Crimean Congo hemorrhagic fever virus (CCHFV) under the Nairoviridae family.

[0039] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the family Arenaviridae: lymphocytic choriomeningitis virus LCMV, Machupo virus (MACV) and Lassa virus.

[0040] In a preferred embodiment of the present invention, the application includes: the active phenolic acid inhibits the viral activity by targeting the Cap-dependent nuclease of the segmented RNA virus.

[0041] In a third aspect, the present invention provides the use of flavonoids or pharmaceutically acceptable salts thereof in the preparation of drugs against segmented RNA viruses or Cap-dependent nuclease inhibitors, wherein the flavonoids are selected from at least one of glycyrrhiza flavonoid A, glycyrrhiza isoflavone A, glycyrrhiza flavonoid B, glycyrrhiza flavonols, glabridol, northwest glycyrrhiza isoflavones, luteolin, mulberry flavonoids, sophora flavescens alcohol A, dehydrated icariin, isodehydroicariin, isopsoralen dihydroflavone, isoxanthohumol and paper mulberry flavonol F.

[0042] After screening and verification, the inventors found that the above flavonoids have good anti-segmented RNA virus effects at the in vitro level and the cellular level.

[0043] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales.

[0044] The segmented RNA virus is selected from at least one of Severefever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the family Leucoviridae. The viruses of the family Leucoviridae include but are not limited to the genus Geckovirus, the genus Parsivirus, the genus Termitovirus and the genus Tenuivirus.

[0045] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one of Songling virus (SGLV) and Crimean Congo hemorrhagic fever virus (CCHFV) under the Nairoviridae family;

[0046] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one of the lymphocytic choriomeningitis virus LCMV, Machupo virus (MACV) and Lassa virus under the Arenaviridae family;

[0047] In a preferred embodiment of the present invention, the segmented RNA virus is selected from at least one virus of the genus influenza A virus, influenza B virus, influenza C virus and togovirus under the family Orthomyxoviridae. In a preferred embodiment of the present invention, the application includes: the flavonoid substance inhibits the viral activity by targeting the Cap-dependent nuclease of the segmented RNA virus.

[0048] In a preferred embodiment of the present invention, the drug further comprises a pharmaceutically acceptable excipient.

[0049] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0050] Example 1

[0051] In this example, an experiment was conducted to detect the inhibitory effect of the target compound on the enzyme activity of the segmented negative-strand RNA virus SFTSV, HRTV, GTV, LCMV and IAV endonuclease EN.

[0052] The experimental steps are as follows:

[0053] 1. The RNA single-stranded substrate used in the experiment is SEQ ID NO: 1: 5'-FAM-AGGAAGAUUAAUAAUUUUCCU-BHQ1-3', which is suitable for SFTSV, HRTV, GTV, LCMV and IAV endonuclease activity detection experiments;

[0054] 2. Configuration containing Mn 2+ Reaction buffer: 50 mM HEPES pH 7.8, 150 mM KCl and 1 mM MnCl2;

[0055] 3. Prepare the experimental reaction system: dilute the drug to 10mM (10×) with DMSO, and then dilute the drug three times with DMSO, for a total of 6 or 7 concentrations. The nuclease protein is diluted to 1.25μM (1.25×) with the reaction buffer. The total reaction volume is 25μl, add 2.5μl of the corresponding drug stock solution to each reaction, add 2.5μl DMSO to the negative control group, and then add 20μl of protein diluent, mix well in the ELISA plate and incubate at 37°C for 30min;

[0056] 4. Turn on the microplate reader (BioTek SYNERGY H1 microplate reader) in advance, set λex / λem=485nm / 535nm, and preheat to 37°C;

[0057] 5. Reaction: Dilute the RNA single-stranded substrate to 1 μM with reaction buffer, add 2.5 μl to each reaction system to make the RNA reaction concentration 100 nM. After mixing, put it into the microplate reader and detect the fluorescence intensity once a minute;

[0058] 6. The reaction rate in the first five minutes of the reaction (reaction rate is the fluorescence change value per unit time, reaction rate = fluorescence change value / reaction time) represents the endonuclease activity, and the DMSO well endonuclease reaction rate is used as a reference to calculate the inhibition rate of the drug treatment group ((1-drug treatment group reaction rate / DMSO treatment group reaction rate) × 100%). According to the inhibition rate of the drug treatment groups with different concentrations, Prism8.0 software was used to fit the drug to enzyme activity inhibition rate curve, and the half effective inhibition concentration of each drug on the endonuclease was calculated. The curve and IC of each drug were obtained by fitting. 50 Reference Figure 1 .

[0059] The results showed that licorice flavonoids C had a significant inhibitory effect on the enzyme activity of SFTSV, HRTV, GTV, LCMV and IAV endonucleases EN. Salvianolic acid A, B and C also had a significant inhibitory effect on the enzyme activity of segmented negative-strand RNA viruses SFTSV, HRTV, GTV and LCMV endonucleases EN.

[0060] Example 2

[0061] This example conducts an experiment to detect the antiviral activity of the target compound against SFTSV, HRTV, and GTV.

[0062] Vero cells in logarithmic growth phase were cultured at 4×10 4Cells / well were inoculated in a 48-well cell culture plate and cultured in a 37°C, 5% CO2 incubator for 14-18h. The initial drug concentration was 150μM, and the drug was diluted three times in DMEM containing 2% fetal bovine serum, with a total of six or seven concentration gradients; a control group of drug solvent dimethyl sulfoxide (0.1% DMSO, diluted with DMEM containing 2% fetal bovine serum) was set. After removing the cell supernatant, 200μl of drug solution was added to the cells and incubated at 37°C for 1h. 10μl of virus dilution (multiplicity of infection MOI = 0.1) was added to each well, and the cells were infected at 37°C for 1h. The infected material was fully removed and the cells were washed once with 200μl PBS. 200μl of drug culture medium or culture medium containing DMSO of the corresponding concentration was added to the well again, and culture was continued for 36h, and 150μl of cell culture supernatant was collected. The number of viral copies was determined by qRT-PCR. All nucleic acids were extracted using a DNA / RNA Extraction Kit (Prepackaged, Novagen), and the copy number was detected using a HiScript II One Step qRT-PCR SYBR Green Kit (Novagen).

[0063] The copy number was detected using the standard curve method: SFTSV used an SFTSV NP plasmid with a known copy number as a standard, and specific primers targeted NP (SEQ ID NO: 2 (SFTSV-NP-F): TGCCTTCACCAAGACTATCAATGT; SEQ ID NO: 3 (SFTSV-NP-R): GGGTCCCTGAAGGAGTTGTAAA); GTV used an NP plasmid with a known copy number as a standard, and specific primers targeted the NP conserved region (SEQ ID NO: 4 (GTV-NP-F): TTGCCCTCACTCGAGGAAAC; SEQ ID NO: 5 (GTV-NP-R) TGAGGCTCATAACAGCTGGC); HRTV used an NP plasmid with a known copy number as a standard, and specific primers targeted the NP conserved region (SEQ ID NO: 6 (HRTV-NP-F): GTTGAGATTGGCAACGAGCC; SEQ ID NO: 7 (HRTV-R): GGATCCAGGCCCTCATAAGC). According to the standard curve, the copy number of each sample was calculated. The copy number of the DMSO group was used as a reference to calculate the inhibition rate of the drug-treated group ((1-viral copy number of the drug-treated group / viral copy number of the DMSO group) × 100%). According to the inhibition rate of the drug-treated groups with different concentrations, the Prism 8.0 software was used to fit the drug inhibition rate curve, and the half-effective inhibition concentration of glycyrrhizin C and salvianolic acid A, B, C on SFTSV, GTV and HRTV was calculated. The results are shown in Figure 2As shown in ad, the results showed that glycyrrhizin flavonoids C and salvianolic acids A, B, and C could significantly inhibit the replication and amplification of SFTSV, GTV, and HRTV.

[0064] Example 3

[0065] This example provides an experiment to detect the antiviral activity of target compounds glycyrrhizin C and salvianolic acids A, B, and C against LCMV.

[0066] The method for detecting the activity of anti-LCMV virus is as in Example 1, the cells are changed to A549 cells, the MOI is 0.01, the starting concentration of the anti-LCMV drug is 150 μM, the drug is diluted three times, and there are 7 drug gradients in total; a control group of drug solvent dimethyl sulfoxide (DMSO, 0.1% DMEM diluted with 2% fetal bovine serum) is set. The supernatant is collected 48 hours after virus infection for subsequent detection. LCMV uses an L fragment plasmid with a known copy number as a standard, and specific primers target the L conserved region SEQ ID NO: 8 (LCMV-LF): GTAGTGGTCATGGCATCTTACC; SEQ ID NO: 9 (LCMV-LR): GAGAGGAGAAAGGCACCAATAG). The method of administration, detection method, and inhibition rate calculation method are consistent with those in Example 2. The results refer to Figure 2 As shown in ad, the results showed that glycyrrhizin flavonoids C and salvianolic acids A, B, and C had significant anti-LCMV virus activity.

[0067] Example 4

[0068] This example provides an experiment to detect the antiviral activity of the target compound Glycyrrhizin C against IAV.

[0069] The method for detecting the activity against IAV virus is similar to that in Example 1, except that the cells are changed to MDCK cells, the MOI is 0.01, and the diluent is the cell maintenance medium of IAV. The supernatant is collected 48 hours after virus infection for subsequent detection. IAV uses an HA fragment plasmid with a known copy number as a standard, and specific primers target HA (SEQ ID NO: 10 (IAV-HA-F): GGGTCCCTGAAGGAGTTGTAAA; SEQ ID NO: 11 (IAV-HA-R): GAAGCAGTGGGTCGCATTCT). The drug dilution multiple, administration method, detection method, and inhibition rate calculation method are consistent with those of SFTSV in Example 2. The results are shown in Figure 2 As shown in a. The results showed that licorice flavonoids C has obvious anti-IAV virus activity.

[0070] Example 5

[0071] This example provides an antiviral activity detection experiment of the target compounds glycyrrhizin C and salvianolic acid A in a mouse model.

[0072] The in vivo antiviral (SFTSV) test of flavonoid C of Licorice was performed on 8-week-old female C57BL / 6 mice. A solvent control group, a positive control group (T-705 group (Favipiravir group), 150 mg / kg / time) and three drug groups (5 mg / kg / time, 10 mg / kg / time and 20 mg / kg / time) were set up respectively. Four mice were set up in each group and infected with 1E4 PFU of SFTSV virus by intraperitoneal injection. 100 μl was injected into the tail vein of the mice half an hour after the attack. The solvent control group was injected with the same volume of solvent (5% DMSO + 15% Solutol HS15 + 80% saline) by tail vein. The positive control group was gavaged with 100 μl (the solvent was 0.5% sodium carboxymethyl cellulose, used after high pressure sterilization), and then the drugs were administered in the same way every 12 hours, and the changes in body weight were observed. After euthanizing the mice 48 hours after the attack, blood was collected, and the spleen, liver and kidneys were dissected and removed. Each tissue was ground and lysed to extract RNA, and the expression level of viral genomic RNA was detected by qRT-PCR.

[0073] The in vivo antiviral (LCMV) test of salvianolic acid A used 8-week-old female Balb / c mice, and set up a solvent control group, a positive control group (T-705 group, 300 mg / kg / time) and two drug groups (20 mg / kg / time and 40 mg / kg / time), with 4 mice in each group, and infected with 1E5 PFU of LCMV virus by intraperitoneal injection. Half an hour after the mice were challenged with the virus, 100 μl was injected into the tail vein, the solvent control group was injected with the same volume of solvent (5% DMSO + 95% saline), and the positive control group was gavaged with 100 μl (the solvent was 0.5% sodium carboxymethyl cellulose, used after high-pressure sterilization), and the drugs were administered in the same way every 24 hours, and the changes in body weight were observed. After 72 hours after the virus was challenged, the mice were euthanized and dissected to remove the spleen and liver. Each tissue was ground and lysed to extract RNA, and the expression level of viral genomic RNA was detected by qRT-PCR.

[0074] All mouse experiments were performed under an animal biosafety level 2 (ABSL-2) environment, and all procedures and ethical regulations involving animals in the experiments were reviewed and approved by the Animal Welfare and Ethics Committee of our institution.

[0075] Figure 3 Figure a in the figure is an overview of the experimental process of drug administration and injection of SFTSV. Figure 3 Figure b shows the weight change of mice after drug administration. Figure 3Figure c shows the expression level of viral genome RNA in mouse spleen, kidney, liver and whole blood under different treatments. Figure 3 Figure d in the figure is an overview of the experimental process of drug administration and injection of LCMV. Figure 3 Figure e in the figure shows the weight change of mice after drug administration. Figure 3 Figure f shows the expression level of viral genome RNA in mouse spleen and liver under different treatments.

[0076] The results showed that glycyrrhizin flavonoids C and salvianolic acid A had good antiviral activity in mouse models.

[0077] Example 6

[0078] The effects of 16 natural flavonoid extracts on anti-SFTSV endonuclease activity in vitro and anti-SFTSV virus activity in cells were tested using the same experimental methods as in Examples 1 and 2.

[0079] Results reference Figure 4 As shown, the results showed that glycyrrhiza flavonoid C analogs such as glycyrrhiza flavonoid A, glycyrrhiza isoflavone A, glycyrrhiza flavonoid B, glycyrrhiza flavonol, glabridol, northwest glycyrrhiza isoflavone, luteolin, mulberry flavonoid, sophora flavescens alcohol A, dehydrated icariin, isodehydroicariin, isopsoralen dihydroflavone, isoxanthohumol and paper mulberry flavonol F had anti-SFTSV activity at the cellular level and the effect of inhibiting SFTSV endonuclease activity in vitro.

[0080] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of glycyrrhizin flavone C or a pharmaceutically acceptable salt thereof in the preparation of drugs against segmented RNA viruses or Cap-dependent endonuclease inhibitors.

2. The use according to claim 1, characterized in that: The segmented RNA virus is selected from at least one virus in the order Bunyavirales and the family Orthomyxoviridae; Preferably, the segmented RNA virus is a segmented negative-strand RNA virus.

3. The use according to claim 1, characterized in that: The segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales; Preferably, the segmented RNA virus is selected from at least one virus of Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the family Leukoviridae; Preferably, the segmented RNA virus is selected from at least one virus selected from Songling virus (SGLV) and Crimean Congo hemorrhagic fever virus (CCHFV) under the Nairoviridae family; Preferably, the segmented RNA virus is selected from at least one virus of Lymphocytic Choriomeningitis Virus LCMV, Machupo virus (MACV) and Lassa virus under the Arenaviridae family; Preferably, the segmented RNA virus is selected from at least one virus of the genus Influenzavirus, genus Influenzavirus, genus Influenzavirus and genus Togotovirus under the family Orthomyxoviridae.

4. The use according to any one of claims 1 to 3, characterized in that: The application includes: the licorice flavonoids C inhibits viral activity by targeting the Cap-dependent nuclease of segmented RNA viruses.

5. Use of active phenolic acid or a pharmaceutically acceptable salt thereof in the preparation of a drug against segmented RNA viruses or a Cap-dependent endonuclease inhibitor, characterized in that: The active phenolic acid is selected from at least one of salvianolic acid A, salvianolic acid B and salvianolic acid C.

6. The use according to claim 5, characterized in that: The segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales; Preferably, the segmented RNA virus is selected from at least one virus of Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the family Leukoviridae; Preferably, the segmented RNA virus is selected from at least one of Songling virus (SGLV) and Xinjiang hemorrhagic fever virus (CCHFV) under the Nairoviridae family; Preferably, the segmented RNA virus is selected from at least one virus of Lymphocytic Choriomeningitis Virus LCMV, Machupo virus (MACV) and Lassa virus under the Arenaviridae family; Preferably, the application includes: the active phenolic acid inhibits viral activity by targeting Cap-dependent endonucleases of segmented RNA viruses.

7. Use of flavonoids or pharmaceutically acceptable salts thereof in the preparation of drugs against segmented RNA viruses or Cap-dependent endonuclease inhibitors, characterized in that: The flavonoids are selected from at least one of glycyrrhiza flavonoids A, glycyrrhiza isoflavones A, glycyrrhiza flavonoids B, glycyrrhiza flavonols, glabridol, glycyrrhiza uralensis isoflavones, luteolin, mulberry flavonoids, sophora flavescens alcohol A, dehydrated icariin, isodehydroicariin, isopsoralen dihydroflavone, isoxanthohumol and paper mulberry flavonol F.

8. The use according to claim 7, characterized in that: The segmented RNA virus is selected from at least one virus in the Bunyavirales and Orthomyxoviridae.

9. The use according to claim 8, characterized in that: The segmented RNA virus is selected from at least one virus of the families Phenuiviridae, Nairoviridae and Arenaviridae under the order Bunyavirales; Preferably, the segmented RNA virus is selected from at least one virus of Severe fever with thrombocytopenia syndrome virus (SFTSV), Heartland virus (HRTV) and Guertu virus (GTV) under the family Leukoviridae; Preferably, the segmented RNA virus is selected from at least one of Songling virus (SGLV) and Xinjiang hemorrhagic fever virus (CCHFV) under the Nairoviridae family; Preferably, the segmented RNA virus is selected from at least one virus of Lymphocytic Choriomeningitis Virus LCMV, Machupo virus (MACV) and Lassa virus under the Arenaviridae family; Preferably, the segmented RNA virus is selected from at least one virus of the genus Influenzavirus, genus Influenzavirus, genus Influenzavirus, genus C Influenzavirus and genus Togotovirus under the family Orthomyxoviridae; Preferably, the application includes: the flavonoids inhibit viral activity by targeting Cap-dependent endonucleases of segmented RNA viruses.

10. The use according to any one of claims 1 to 3, the use according to any one of claims 5 to 6, or the use according to any one of claims 7 to 9, characterized in that: The drug also includes pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Application for liquiritin and derivatives of liquiritin in preparation of drugs for treating and / or preventing novel coronaviruses

    CN111297882A

  • Traditional Chinese medicine flavonoid anti-influenza A virus KA series medicine and application

    CN113948162A

  • Pharmaceutical composition for preventing and treating new coronavirus infection as well as medicine and application thereof

    CN116059229A

  • Antiviral agent

    JP2022104747A

  • Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract

    US20130041023A1

Cited By

  • Application of isodehydroicaritin in preparation of I-type herpes simplex virus resisting medicine

    CN119564666A

  • Application of isodehydroicariin in the preparation of drugs against herpes simplex virus type Ⅰ

    CN119564666B